Business
Initiation of 200 patient US ovarian cancer study
Initiation of 200 patient US ovarian cancer study.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 3222F Angle PLC 27 July 2016 \n\n\n\n\n\nFor immediate release\n\n\n 27 July 2016\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nINITIATION OF 200 PATIENT UNITED STATES OVARIAN CANCER STUDY \n \nLeading United States cancer centre recruiting patients; complements recently started European study also in ovarian cancer\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that it has initiated an ovarian cancer study in the United States, in addition to its recently opened European ovarian cancer study. The US study is being led by Dr Richard Moore at the University of Rochester Medical Center Wilmot Cancer Institute (New York State). \n \nPreparation and approvals for the US ovarian cancer study (known as the ANG-003 EMBER study) have been ongoing over recent months. The study has now been formally opened and the first few patients have already been recruited.\n \nThe EMBER study is designed to enrol approximately 200 women with a diagnosed pelvic mass who are scheduled to undergo biopsy, laparotomy or laparoscopic surgery at the University of Rochester Medical Center. Enrolment will continue until a total of 50 evaluable women with a histopathologically confirmed malignancy have been identified. Blood from consenting patients will be processed using the ParsortixTM system to harvest any circulating tumour cells (CTCs) that may be present for evaluation. The Parsortix harvests from the women enrolled into the study will be evaluated for the presence of markers associated with malignancy in ovarian cancer cells. These results will then be compared with the histopathological diagnoses post-surgery to assess their association with whether the pelvic mass is benign or malignant.\n \nAdditionally, a portion of the Parsortix harvest from each patient will be stored so that it can subsequently be used for verification of the molecular markers identified in ANGLE's European ovarian cancer study (ANG-001) as being optimal for the detection of ovarian cancer CTCs harvested by the Parsortix system. \n \nOvarian cancer surgery is highly complex and maximal tumour removal has a very strong impact on survival. Women with the diagnosis or a strong indication of ovarian cancer can be refe...